What is peptide therapy, and how does it differ from conventional pharmacology?

Peptide therapy refers to the investigational use of short amino acid chains (peptides) to modulate biological processes. Unlike conventional drugs that often create new pharmacological effects by blocking or activating specific targets, peptides typically work by amplifying or modulating the body's own signaling pathways. This mechanistic difference means peptide research often focuses on restoring or enhancing natural physiological functions rather than overriding them.

Which peptide categories have the strongest research support?

Tissue repair peptides (BPC-157, TB-500, GHK-Cu) have the most extensive preclinical literature, with hundreds of published studies. Growth hormone axis peptides (CJC-1295, Ipamorelin, Sermorelin) have clinical trial data in specific contexts. Cognitive peptides (Semax, Selank) have a more limited but growing research base, primarily from Eastern European studies. Metabolic and longevity peptides (MOTS-c, Epitalon) are at earlier stages of investigation.

Are peptide therapies approved for clinical use?

Most research peptides discussed on CompoundGuide are not approved by the FDA, EMA, or MHRA for any therapeutic indication. A few exceptions exist: Sermorelin was previously FDA-approved as a diagnostic agent (Geref, now discontinued), and Tesamorelin is approved for HIV-associated lipodystrophy (Egrifta). The majority of compounds remain restricted to research settings.

Can peptides from different categories be combined in research?

Theoretical synergy exists between peptide categories — for example, healing peptides combined with metabolic peptides might support both tissue repair and energy metabolism. However, direct evidence for cross-category combinations is extremely limited. Most combination research has focused on same-category pairing (e.g., CJC-1295 + Ipamorelin for GH axis; BPC-157 + TB-500 for healing).

How do I evaluate the quality of peptide research?

High-quality peptide research is published in peer-reviewed journals indexed in PubMed. Key indicators of reliability include: randomized controlled design (for clinical studies), clearly described methodologies, transparent disclosure of funding sources, and replication of findings across independent research groups. Preclinical studies should specify the model organism, dosing parameters, and measured outcomes. Be cautious of claims based solely on anecdotal reports or unverified sources.

Research Guide

Peptide Therapy Benefits

Explore the scientific research behind peptide therapy benefits across tissue repair, cognitive function, metabolic health, longevity, and anti-aging. Evidence-based guide with PubMed citations.

Last updated May 16, 2026 6 min read

Type "do peptides work" into a search bar and you will get one blended answer — which is the first mistake. "Peptides" is not one thing. A gut-repair compound, a growth hormone secretagogue, and a mitochondrial signal have about as much in common as a hammer, a thermostat, and a battery: all tools, wildly different jobs.

What actually connects them is method. Peptides are short amino-acid chains — typically 3–50 residues — that tend to work by modulating the body's own signaling networks rather than forcing a single receptor, which research suggests may offer distinct advantages where tissue regeneration, metabolic control, or cognitive function are the goals. Their size lets them cross biological barriers without the immunogenicity risks that complicate larger protein therapeutics.

This guide maps the major research categories — tissue repair, growth hormone, cognitive support, metabolic health, anti-aging — and links each to the compounds leading its evidence base. Treat it as a trailhead rather than a destination: pick the category matching your question, then follow the dedicated pages into mechanistic depth.

Overview

Peptide research sorts by biological effect, not by brand name: some compounds accelerate tissue repair, others nudge growth hormone secretion, others influence cognitive pathways, metabolic regulation, or immune function. Lumping them together produces noise; sorting them produces insight.

Five categories dominate the current literature, each supported by preclinical studies and, in places, early-phase clinical trials. Each section below names its lead compounds, sketches what the evidence covers, and links out to dedicated pages for mechanistic depth.

Quick Comparison

Compound	Origin	Mechanism	Half-life	Admin Routes	Research Status
BPC-157	Synthetic pentadecapeptide (derived from gastric juice protein)	VEGF/EGF upregulation, mTOR pathway, nitric oxide system	~hours (preclinical estimate)	Subcutaneous, Intramuscular, Oral	Preclinical
TB-500	Synthetic fragment of Thymosin Beta-4 (aa 17-23)	Actin sequestration, VEGF angiogenesis, NF-κB suppression	~days (based on Tβ4 data)	Subcutaneous, Intramuscular	Preclinical
GHK-Cu	Naturally occurring copper tripeptide (Gly-His-Lys + Cu²⁺)	Copper-dependent collagen crosslinking, antioxidant gene expression	Minutes to hours in plasma	Subcutaneous, Topical	Preclinical + topical RCTs
CJC-1295	Synthetic GHRH analogue (with DAC for extended half-life)	GHRH receptor agonism → pulsatile GH secretion	6–8 days (with DAC); ~30 min (without DAC)	Subcutaneous, Intramuscular	Preclinical
Ipamorelin	Synthetic pentapeptide ghrelin mimetic	Selective GHSR-1a agonism → GH release (minimal cortisol/prolactin effect)	~2 hours	Subcutaneous, Intramuscular	Preclinical
Sermorelin	Synthetic GHRH(1-29) fragment	GHRH receptor activation → endogenous GH pulse amplification	~11–12 min (IV); longer subcutaneous	Subcutaneous, Intravenous	Clinical (FDA-approved diagnostic)
Tesamorelin	Synthetic GHRH analogue (modified for stability)	GHRH receptor agonism → IGF-1 elevation → visceral fat reduction	~26–38 min (IV); ~4–5 hours (SC estimated)	Subcutaneous	Clinical (FDA-approved for HIV lipodystrophy)
Semax	Synthetic ACTH(4-10) fragment with Pro-Gly-Pro modification	BDNF upregulation, enkephalinase inhibition, neurotrophic signaling	Short (minutes); nasal spray extends local bioavailability	Intranasal, Subcutaneous	Clinical (approved in Russia/CIS)
Selank	Synthetic tuftsin analogue with Pro-Gly-Pro modification	Enkephalinase inhibition, IL-6/TNF-α modulation, GABAergic interaction	Short (minutes); intranasal improves CNS access	Intranasal, Subcutaneous	Clinical (approved in Russia/CIS)
MOTS-c	Mitochondrial-derived peptide (encoded in mtDNA 12S rRNA region)	AMPK activation → insulin sensitivity, folate cycle regulation	Short in plasma (minutes); cellular effects persist	Subcutaneous, Intraperitoneal, Intravenous	Preclinical
AOD-9604	Modified hGH fragment (aa 177-191) with Tyr→Ala substitution	β3-adrenergic receptor pathway → lipolysis without IGF-1 elevation	~2–3 hours (limited PK data)	Subcutaneous, Oral	Preclinical
Epitalon	Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin	Telomerase activation, pineal melatonin regulation, p53 modulation	Short (minutes); biological effects persist beyond clearance	Subcutaneous, Intranasal	Preclinical
KPV	Synthetic tripeptide (Lys-Pro-Val) — α-MSH fragment	TNF-α/IL-6 suppression, intestinal epithelial barrier integrity	Short (minutes; limited PK data)	Subcutaneous, Oral, Topical	Preclinical

Compounds in This Guide

BPC-157

Gastrointestinal protection & systemic tissue repair

Full profile â†’

Tissue Repair and Regeneration

If peptide research has a flagship category, this is it. BPC-157 , TB-500 , and GHK-Cu have each been investigated across skin, tendon, ligament, muscle, and gastric mucosa — the broadest tissue spread of any group on this page.

The division of labor is neat. BPC-157 appears to upregulate VEGF and EGF, driving angiogenesis and cellular proliferation ; TB-500 regulates actin dynamics, enabling the cell migration wound closure requires ; GHK-Cu supplies copper for collagen cross-linking, upgrading the structural quality of the final repair .

Read together, they suggest a distinctive philosophy: supporting the body's existing repair cascades rather than overriding them — the opposite logic to replacement hormones.

A newer angle targets inflammation itself. ** KPV **, a tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH), has been studied for suppressing TNF-α and IL-6 — key drivers of chronic inflammation — while reinforcing intestinal epithelial barrier integrity . That dual profile positions KPV at the junction of immune modulation and tissue repair, especially in gastrointestinal contexts.

gut-healing tendon-repair wound-healing injury-recovery

CJC-1295

Growth hormone-releasing hormone analogue

Full profile â†’

Growth Hormone Axis Modulation

The second pillar prompts the pituitary rather than replacing its output. CJC-1295 , Ipamorelin , Sermorelin , and Tesamorelin each pull a different lever on the hypothalamic-pituitary-somatotropic axis to raise endogenous GH release.

The shorthand version: CJC-1295 is a modified GHRH analogue producing sustained GH elevation ; Ipamorelin mimics ghrelin through an entirely separate signaling pathway ; Sermorelin replicates natural GHRH with a short half-life that hugs physiological pulsatility . The open question — whether preserved feedback loops yield different long-term outcomes than direct GH administration — spans body composition, metabolic health, and possibly longevity. All applications remain investigational.

muscle-growth fat-loss anti-aging

GHK-Cu

Skin regeneration & collagen synthesis

Full profile â†’

Anti-Aging and Skin Health

Some peptides fade as we age — and one decline is unusually well documented. Plasma GHK-Cu falls by more than 60% between young adulthood and age 60 , tracking visible and functional markers of aging.

Research suggests GHK-Cu may support collagen synthesis, elastin production, and antioxidant gene expression — credentials that made it dermatology's most-studied topical peptide, spanning wound-healing and skin-quality research.

** AOD-9604 ** recurs here too, investigated for fat-metabolism effects without the broader GH-axis implications of full-length hormone administration . Same trend, different tissue: isolate the useful signal, skip the systemic baggage.

skin-health wound-healing anti-aging

MOTS-c

Mitochondrial-encoded peptide studied for metabolic regulation and longevity

Full profile â†’

Metabolic Health and Longevity

Mitochondria turned out to be signaling players too. MOTS-c , a 16-amino-acid peptide encoded inside mitochondrial DNA, has been studied for effects on insulin sensitivity and glucose homeostasis — apparently functioning as a systemic metabolic signal that even translocates to the nucleus under stress to regulate energy-balance gene expression.

Epitalon , a synthetic tetrapeptide derived from epithalamin, has been explored for telomerase activity and cellular aging markers . Evidence remains preliminary, but these compounds plant peptides squarely at the metabolism-meets-longevity intersection.

** AOD-9604 illustrates the category's surgical streak: a modified human growth hormone fragment (aa 177-191) investigated for stimulating lipolysis through the β3-adrenergic receptor pathway without elevating IGF-1 or blood glucose** . Isolate one useful activity from a larger molecule, leave the rest behind — a defining theme of modern peptide research.

metabolic-health anti-aging fat-loss

Semax

ACTH-derived nootropic peptide studied for BDNF modulation and cognitive performance

Full profile â†’

Cognitive and Neurological Support

Compounds that cross the blood-brain barrier open a different frontier: cognition itself. Semax and Selank — both derived from adrenocorticotropic hormone (ACTH) fragments, both products of Russian and Eastern European research programs — lead this category.

Semax has been investigated for raising brain-derived neurotrophic factor (BDNF) expression and supporting cognitive performance under stress ; Selank for anxiolytic effects involving GABAergic modulation . Their direction differs from every peripheral category above — nervous system rather than tissue. The evidence base runs thinner than for repair peptides, but the mechanistic grounding is real, and as the closing section shows, the categories may be more connected than they first appear.

cognitive-enhancement neuroprotection mood-support

How They Work Together

Integrating Peptide Research Across Categories

The categories above look separate on a page. In a body, they talk constantly: metabolic health shapes repair capacity, cognition depends on vascular health, and the GH-IGF-I axis touches both body composition and skin quality.

That interconnection poses one of the field's most interesting open questions: could compounds from different categories interact systemically — for better or worse? Most published studies examine single compounds in isolation, which leaves the systems-level question wide open and makes it a genuine frontier rather than a settled topic. Existing combination studies stay inside single lanes: CJC-1295 + Ipamorelin on the GH axis, BPC-157 + TB-500 in healing. Broader integration has not been systematically explored.

The predefined research stacks mirror that caution. The Healing Stack ( BPC-157 + TB-500 ), the Glow Blend (BPC-157 + GHK-Cu ), and the Growth Hormone Stack ( CJC-1295 + Ipamorelin ) each study complementarity within one therapeutic category. Cross-category combinations remain theoretical — a frontier, not a finding — and the next decade of studies will decide which way it breaks.

Frequently Asked Questions

: Peptide therapy refers to the investigational use of short amino acid chains (peptides) to modulate biological processes. Unlike conventional drugs that often create new pharmacological effects by blocking or activating specific targets, peptides typically work by amplifying or modulating the body's own signaling pathways. This mechanistic difference means peptide research often focuses on restoring or enhancing natural physiological functions rather than overriding them.
: Tissue repair peptides (BPC-157, TB-500, GHK-Cu) have the most extensive preclinical literature, with hundreds of published studies. Growth hormone axis peptides (CJC-1295, Ipamorelin, Sermorelin) have clinical trial data in specific contexts. Cognitive peptides (Semax, Selank) have a more limited but growing research base, primarily from Eastern European studies. Metabolic and longevity peptides (MOTS-c, Epitalon) are at earlier stages of investigation.
: Most research peptides discussed on CompoundGuide are not approved by the FDA, EMA, or MHRA for any therapeutic indication. A few exceptions exist: Sermorelin was previously FDA-approved as a diagnostic agent (Geref, now discontinued), and Tesamorelin is approved for HIV-associated lipodystrophy (Egrifta). The majority of compounds remain restricted to research settings.
: Theoretical synergy exists between peptide categories — for example, healing peptides combined with metabolic peptides might support both tissue repair and energy metabolism. However, direct evidence for cross-category combinations is extremely limited. Most combination research has focused on same-category pairing (e.g., CJC-1295 + Ipamorelin for GH axis; BPC-157 + TB-500 for healing).
: High-quality peptide research is published in peer-reviewed journals indexed in PubMed. Key indicators of reliability include: randomized controlled design (for clinical studies), clearly described methodologies, transparent disclosure of funding sources, and replication of findings across independent research groups. Preclinical studies should specify the model organism, dosing parameters, and measured outcomes. Be cautious of claims based solely on anecdotal reports or unverified sources.

Summary

From the cellular mechanics of wound closure to mitochondrial fuel-switching to the molecular roots of cognitive resilience, peptide research covers astonishing range — unified by one method: isolating specific signaling sequences from larger proteins and studying them under controlled conditions.

Where the evidence stands is unambiguous: peptides are biologically active compounds with documented mechanisms in preclinical models. What controlled human trials have not established is whether those mechanisms translate into safe, effective, reproducible therapeutic outcomes.

The responsible path forward runs through primary literature on PubMed, clear-eyed awareness of regulatory status, and refusal to leap from animal models to human conclusions without caution. Educational context is what this guide provides; experimental decisions belong to peer-reviewed evidence and institutional oversight — and now, to whichever category you explore next.